Fulgent Genetics, Inc. (FLGT) Stock Forecast
FLGT analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $19.00 average of analyst targets
- Upside to target
- −4.1% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $1.00
- 52-week range
- $13.79 – $30.85
FLGT analyst ratings
1 analystsNumber of analysts at each rating.
FLGT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FLGT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.65 | −$0.65 | −$0.65 | $0.14 | −564.3% | 1 |
| Current fiscal year (2026) | −$2.27 | −$2.27 | −$2.27 | $0.42 | −640.5% | 1 |
| Next fiscal year (2027) | −$1.38 | −$1.38 | −$1.38 | −$2.27 | +39.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FLGT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $86.3M | $86.3M | $86.3M | +2.6% | 1 |
| Current fiscal year (2026) | $331.7M | $331.7M | $331.7M | +2.8% | 1 |
| Next fiscal year (2027) | $382.7M | $382.7M | $382.7M | +15.4% | 1 |
FLGT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FLGT revenue: reported and forecast
FLGT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.36 | −$0.36 | −$0.36 | −$0.65 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | −$1.55 | −$1.55 | −$1.55 | −$2.27 | — | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | −$1.15 | −$1.15 | −$1.15 | −$1.38 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FLGT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FLGT beat in 9 of 12.
What analysts expect from FLGT
1 analysts cover Fulgent Genetics; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $19.00, 4.1% below the latest close of $19.81. Analysts expect earnings of −$2.27 per share for 2026, −640.5% from a year earlier. For 2027 the average estimate is −$1.38 per share on revenue of $382.7 million. Fulgent Genetics beat the EPS estimate in 9 of the last 12 quarters.
Related: FLGT income statement, FLGT key metrics, FLGT chart. See the FLGT stock overview for the latest quote and news.
FLGT forecast FAQ
What is Fulgent Genetics's price target?
The average analyst price target for Fulgent Genetics is $19.00, 4.1% below the latest close of $19.81.
Is Fulgent Genetics a buy, hold or sell?
Of 1 analysts covering Fulgent Genetics, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Fulgent Genetics's EPS forecast?
Analysts forecast −$2.27 per share for 2026 (range −$2.27 to −$2.27); for 2027 the estimate is −$1.38.
What is Fulgent Genetics's revenue forecast?
The average revenue estimate for 2026 is $331.7 million, growth of 2.8%; for 2027 it is $382.7 million.
When does Fulgent Genetics report earnings?
Fulgent Genetics is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 after the market closes; the EPS estimate is $1.00.
Does Fulgent Genetics usually beat earnings estimates?
Fulgent Genetics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.